Phase I study of CBT-1(TM) and Taxol® in patients with Taxol® resistant cancers

Cancer Biotherapy and Radiopharmaceuticals

Volumn 15, Issue 2, 2000, Pages 153-159

  Oldham, Robert K ^a,b   Reid, William K ^a   Barnett, Daryl ^b  

^a Cancer Treatment Associates   (United States)

^b CBA Research Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CBT 1; NATURAL PRODUCT; PACLITAXEL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; DRUG INDUCED DISEASE; FEMALE; HUMAN; LUNG CANCER; MALE; MULTIDRUG RESISTANCE; NAUSEA; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME; VOMITING;

EID: 0034068093     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2000.15.153     Document Type: Article

References (32)

1. Bell DR, Gerlach JH, Kartner N, et al. Detection of P-glycoprotein in ovarian cancer. A molecular marker associated with multidrug resistance. J Clin Oncol 1985;3:311-315.
2. Pinedo HM and Giaccone G. P-glycoprotein: a marker of cancer cell behavior. New Engl J Med 1995;333: 1417-1419.
3. Beck W, Cirtain M, Danks M, Felsted R, Safa A, Wolverton J, Suttle D, and Trent J. Pharmacological, molecular and cytogenetic analysis of "atypical" multidrug-resistant human leukemic cells. Cancer Res 1987: 47:5455-5460.
4. Biedler J and Meyers M. Multidrug resistance (Vinca alkaloids, actinomycin D, and anthracycline antibiotics). In: R Gupta (ed.), Drug Resistance in Mammalian Cells, Vol. 2, Anticancer and Other Drugs, pp. 125-140, 1989. Boca Raton, FL: CRC Press.
5. Gerlach J, Kartner N, Bell D, and Ling V. Multidrug resistance. Cancer Surv 1986;5:25-46.
6. Fojo A, Ueda K, Slamon D, Poplack D, Gottesman M, and Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 1987;84:265-269.
7. Yuen A and Sikic B. Multidrug resistance in lymphomas. J Clin Oncol 1994;12:2453-2459.
8. Fojo A, Shen D-W, Mickley L, Pastan I, and Gottesman M. Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug resistance gene. J Clin Oncol 1987;5:1922-1927.
9. Goldstein I, Galski H, Fojo A, Willingham M, Lai S-L, Gazdar A, Pirker R, Green A, Crist W, Brodeur G, Lieber M, Cossman J, Gottesman M, and Pastan I. Expression of a multidrug resistance gene in human tumors. J Natl Cancer Inst 1989;81:116-124.
10. Tsuruo T, Iida H, Tsukagoshi S, and Sakurai Y. Increased accumulation of vincristine and Adriamycin in drug resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res 1982;42:4730-4733.
11. Pennock G, Dalton W, Roeske W, Appleton C, Mosley K, Plezia P, Miller T, and Salmon S. Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration. J Natl Cancer Inst 1991;83:105-110.
12. Samuels B, Mick R, Vogelzang N, Williams S, Schilsky R, Safa A, O'Brien S, and Ratain M. Modulation of vinblastine resistance with cyclosponne: a Phase I study. Clin Pharmacol Ther 1993;54:421-429.
13. Trump D, Smith D, Ellis P, Rogers M, Schold S, Winer E, Panella T, Jordan V, and Fine R. High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: Phase I trial in combination with vinblastine. J Natl Cancer Inst 1992;84:1811-1816.
14. Giaocone G, Linn SC, Welink J, Catimel G, Steltjes H, van der Vijgh WJF, Eeltink C, Vermorken JB, and Pinedo HM. A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors. Clin Cancer Res 1997;3:2005-2015.
15. Leith CP, Chen I-M, Kopecky KJ, et al. Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: Identification of discordant MDR-/efflux+ and MDR1+/efflux-cases. Blood 1995;86:2329-2342.
16. Solary E, Witz B, Caillot D, et al. Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: A randomized multicenter study. Blood 1996;88:1198-1205.
17. Miller TP, Grogan TM, Dalton WS, et al. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high dose verapamil. J Clin Oncol 1991;9:17-24.
18. Ross DD, Wooten PJ, Sridhara R, et al. Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia. Blood 1993;82:1288-1299.
19. List AF, Spier C, Greer J, et al. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 1993;11:1652-1660.
20. Samuels BL, Hollis DR, Rosner GL, Trump DL, ShapiroCL, Vogelzang NJ, and Schilsky RL. Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study. Clin Cancer Res 1997;3:1977-1984.
21. Simon R. Designs for efficient clinical trials. Oncology 1989;3:43-49.
22. Bartlett NL, Lum BL, Fisher GA, Brophy NA, Ehsan MN, Halsey J, and Sikic IB. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. Journ Clin Oncol 1994;12:835-842.
23. Lee EJ, George SL, Caligiuri M, et al. Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leukemia group B study 9420. J Clin Oncol 1999;17(9):2831-
24. CBA Research Inc. Data on file, 1998.
25. Oldham RK, Reid WK, Preisler HD, and Barnett D. A phase I and pharmacokinetic study of CBT-1 as a multidrug resistance modulator in the treatment of patients with advanced cancer. Cancer Biotherapy & Radiopharmaceuticals 1998;13(2):71-80.
26. Kerr DJ, Graham J, Cummings J, Morrison JG, Thompson GG, Brodie MJ, and Kaye SB. The effect of verapamil on the pharmacokinetics of adriamycin. Cancer Chemother Pharmacol 1986;18:239-242.
27. Lum BL, Kaubish S, Yahanda AM, Adler KM, Jew L, Ehsan MN, Brophy NA, Halsey J, Gosland MP, and Sikic BI. Alteration of etoposidepharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 1992; 10: 1635-1642.
28. Speeg KV and Maldonado AL. Effect of the nonimmunosuppressive cyclosporine analog SDZ PSC-833 on colchicine and doxorubicin biliary secretion by the rat in vivo. Cancer Chemother Pharmacol 1994;34:133-136.
29. Boote DJ, Dennis IF, Twentyman PR, Osborne RJ, Laburte C, Hensel S, Smyth JF, Brampton MH, and Bleehen NM. Phase I study of etoposide with SDZ PSC-833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol 1996;14:610-618.
30. Fisher GA, Lum BL, Hausdorff J, And Sikic BI. Pharmacological considerations in the modulation of multidrug resistance. Eur J Cancer 1996;32A:1082-1088.
31. Beketic-Oreskovic L, Duran, Chen G, et al. Decreased mutation rate for cellular resi stance to doxorubicin and suppression of mdr 1 gene activation by the cyclosporiri analogue PSC 833. J Natl Cancer Inst 1995;87:1593-1602.
32. Oldham RK. Treatment of drug resistance: biotherapy or chemotherapy? Cancer Biotherapy & Radiopharmaceuticals 1998;13(2):69-70.